Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2011-07-12
2011-07-12
Ramirez, Delia M (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S320100, C435S252300, C435S325000, C435S069100, C536S023200
Reexamination Certificate
active
07977079
ABSTRACT:
This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.
REFERENCES:
patent: 5389537 (1995-02-01), Raines et al.
patent: 5840296 (1998-11-01), Raines et al.
patent: 6280991 (2001-08-01), Raines
patent: 7098016 (2006-08-01), Raines et al.
patent: 7416875 (2008-08-01), Raines et al.
patent: 7655757 (2010-02-01), Raines et al.
patent: 2005/0261232 (2005-11-01), Strong et al.
patent: 2006/0292137 (2006-12-01), Raines et al.
patent: 2009/0311784 (2009-12-01), Raines et al.
patent: 778024 (2005-03-01), None
patent: 2002301972 (2006-03-01), None
patent: 2306442 (2010-04-01), None
patent: 1896579 (2008-03-01), None
patent: 1023447 (2008-08-01), None
patent: 1910541 (2010-10-01), None
patent: 143036 (2009-09-01), None
patent: 200817144 (2008-05-01), None
patent: 2008517102 (2008-05-01), None
patent: 9919494 (1999-04-01), None
patent: WO 00/31242 (2000-06-01), None
patent: 0040608 (2000-07-01), None
patent: 2006138458 (2006-12-01), None
Kappel et al., Current Opinion in Biotechnology 3:548-553, 1992.
Mullins et al., Hypertension 22(4):630-633, 1993.
Cameron, E., Molecular Biotechnology 7:253-265, 1997.
Mullins et al., J. Clin. Invest. 97(7):1557-1560, 1996.
Houdebine, L., Journal of Biotechnology 98:145-160, 2002.
Phillips, A.,J. Pharm. Pharmacology 53:1169-1174, 2001.
Gardlik et al., Med. Sci. Monit. 11(4):RA110-121, 2005.
Smyth et al., J. Biol. Chem. 238(1):227-234, 1963.
Carsana, A., et al., “Structure of the bovine pancreatic ribonuclease gene: the unique intervening sequence . . . ,” Nucleic Acids Research 16:5491-5502 (1988).
Bosch, M., et al., “A Nuclear Localization Sequence Endows Human Pancreatic Ribonuclease with Cytotoxic Activity,” Biochemistry 43:2167-2177 (2004).
Kobe, B., et al., “Mechanism of Ribonuclease Inhibition by Ribonuclease Inhibitor Protein based on the Crystal Structure . . . ,” J.Mol. Biol. 264:1028-1043 (1996).
Kumar, K., et al., “Selective abolition of pancreatic RNase binding to its inhibitor protein,” PNAS 101:53-58 (2004).
Pous, J., et al., “Three-dimensional Structure of a Human Pancreatic Ribonuclease Variant, a Stem Forward in the Design . . . ,” J. Mol. Biol. 303:49-59 (2000).
Leland, P.A., et al., “Ribonuclease A Variants with Potent Cytotoxic Activity,” Proc. Natl. Acad. Sci. USA 95:10407-10412 (1998).
Leu, Y-J., et al., “Residues Involved in the catalysis, Base Specificity, and Cytotoxicity of Ribonuclease . . . ,” The Journal of Biological Chemistry 278:7300-7309 (2003).
Rajamani, D., et al., “Anchor residues in protein-protein interactions,” PNAS 101:11287-11292 (2004).
Rutkoski, T.J., et al., “Disruption of Shape-Complementarity Markers to Create Cytotoxic Variants of Ribonuclease A,” J. Mol. Biol. 354:41-54 (2005).
Branden et al., Introduction to Protein Structure, Garland Publishing Inc., New York, p. 247, 1991.
Witkowski et al., Biochemistry 38:11643-11650, 1999.
Seffernick et al., J. Bacteriol. 183(8):2405-2410, 2001.
International Search Report dated Nov. 13, 2006 (International Patent Application No. PCT/US2006/023298; filed on Jun. 16, 2006).
Written Opinion dated Dec. 16, 2007 (International Patent Application No. PCT/US2006/023298; filed on Jun. 16, 2006).
International Preliminary Report on Patentability dated Dec. 17, 2007 (International Patent Application No. PCT/US2006/023298; filed on Jun. 16, 2006).
International Search Report dated Aug. 2, 2007 (International Patent Application No. PCT/US2006/023485; filed on Jun. 16, 2006).
Written Opinion dated Dec. 16, 2007 (International Patent Application No. PCT/US2006/023485; filed on Jun. 16, 2006).
International Preliminary Report on Patentability dated Dec. 17, 2007 (International Patent Application No. PCT/US2006/023485; filed on Jun. 16, 2006).
International Search Report dated Nov. 23, 2000 (International Patent Application No. PCT/US19927670; filed on Nov. 22, 1999).
Notice of Allowance dated Apr. 17, 2008 (U.S. Appl. No. 11/454,379, filed Jun. 16, 2006).
Non-Final Rejection dated Aug. 9, 2007 (U.S. Appl. No. 11/454,379, filed Jun. 16, 2006).
Non-Final Rejection dated May 16, 2006 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Non-Final Rejection dated Sep. 5, 2007 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Non-Final Rejection dated Mar. 9, 2007 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Final Rejection dated Oct. 31, 2008 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Advisory Action dated Jan. 13, 2009 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Murphy et al., “Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor”, Biochem. J. Mol. Biol. 354:41-54 (2005).
Quintessence/Biosciences webpages on Evade TM Ribonucleases.
Boix E.. et al., “Role of the N Terminus in RNase A Homologues: Differences in Catalytic Activity. Ribonuclease Inhibitor Interaction and Cytotoxicity,” J. Mol. Biol. 257:992-1007 (1996).
Gaur, D., et al., “Interaction of Human Pancreatic Ribonuclease with Human Ribonuclease Inhibitor,” The Journal of Biological Chemistry 276:24978-24984 (2001).
Kobe B. et al., “A structural basis of the interactions between leucine-rich repeats and protein ligands,” Nature 374:183-186 (1995).
Lee, J.E., et at, “Cytotoxicity of Bovine Seminal Ribonuclease: Monomer versus Dimer,” Biochemistry 44: 15760-15767 (2005).
Leland, P.A., et al., “Endowing Human Pancreatic Ribonuclease with Toxicity for Cancer Cells,” The Journal of Biological Chemistry 276:43095-43102 (2001).
Mitchell, J.C., et at, “Rapid atomic density methods for molecular shape characterization,” Journal of Molecular Graphics and Modelling 19:325-330 (2001).
Pous, et al., “Three-dimensional structure of human RNase 1 delta N7 at 1.9 A resolution”, Acta Cryst. D57:498-505 (2001).
Shaul, et al., “Exploring the Charge Space of Protein-Protein Association: A Proteomic Study”, Proteins: Structure, Function, and Bioinformatics 60:331-352 (2005).
Ontjes et al. (PNAS, Oct. 1969, 64(2):428-35).
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990).
Lazar et al. (Mol. Cell Biol. 8:1247-1252, 1998).
Murthy et al., Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor (Biochem. J., 1992, 281:343-348).
Gura (Science, 1997, 278:1041-1042).
Non-Final Rejection dated Feb. 9, 2011 (U.S. Appl. No. 12/497,038, filed Jul. 2, 2009).
Requirement for Restriction/Election dated Oct. 5, 2010 (U.S. Appl. No. 12/497,038, filed Jul. 2, 2009).
Communication under Rule 71(3) EPC dated May 4, 2010 (Application No. 06784926.5, filed Jun. 16, 2006).
Examination Report dated Aug. 19, 2009 (EP Patent Application No. 06784995.0-2401, filed Jun. 16, 2006).
Examination Report dated Nov. 2, 2010 (EP Patent Application No. 06784995.0-2401, filed Jun. 16, 2006).
Examination Report dated Nov. 21, 2008 (Application No. 06784926.5, filed Jun. 16, 2006).
Examination Report dated Aug. 25, 2008 (European Patent Application No. 99962862821.7, filed Nov. 22, 1999).
Examination Report dated Jan. 20, 2005 (European Patent Application No. 99962862821.7, filed Nov. 22, 1999).
Notice of Allowance dated Jan. 10, 2004 (Australian Patent Application No. 19184/00; filed Mar. 3, 2005).
Examiner's Report dated Jan. 17, 2003 (Australian Patent Application No. 19184/00; filed Mar. 3, 2005).
Office Action dated Nov. 24, 2009 (Canadian Patent Application No. 2,351,735, file
Mitchell Julie C.
Raines Ronald T.
Rutkoski Thomas J.
Quarles & Brady LLP
Ramirez Delia M
Vinarov Sara D.
Wisconsin Alumni Research Foundation
LandOfFree
Nucleic acid constructs encoding cytotoxic ribonuclease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid constructs encoding cytotoxic ribonuclease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid constructs encoding cytotoxic ribonuclease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710359